SCHEMBL2810134

SCHEMBL2810134

COC1CCN(c2cccc(-c3cc(N)nc(-n4nc(C)cc4C)n3)n2)CC1

nearest known ligand 0.71

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ADORA2A P29274 14/20 0.71
ADORA1 P30542 10/20 0.71
TSPO P30536 1/20 0.71
GPR183 P32249 1/20 0.71
SIGMAR1 Q99720 1/20 0.71
GPR35 Q9HC97 1/20 0.71
CYP3A4 P08684 1/20 0.58
KCNH2 Q12809 1/20 0.52
ALOX15 P16050 2/20 0.45
LMNA P02545 1/20 0.45
GAA P10253 1/20 0.45
SMN1; SMN2 Q16637 1/20 0.45
L3MBTL1 Q9Y468 1/20 0.45
MAPT P10636 1/20 0.41
HTT P42858 1/20 0.39
MAP4K4 O95819 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2812966 0.84 ADORA2A (0.69) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL2814740 0.83 ADORA2A (1.00) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL29394328 0.83 ADORA2A (1.00) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL18912230 0.81 ADORA2A (0.57) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL18912275 0.76 ADORA2A (0.52) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL18912381 0.76 ADORA2A (0.52) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL30252565 0.76 ADORA2A (0.52) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL18912239 0.76 ADORA2A (0.52) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL12093611 0.73 HTR3E (0.58) ADORA2AADORA1TSPOGPR183SIGMAR1
SCHEMBL20911174 0.71 ADORA2A (0.47) ADORA2AADORA1TSPOGPR183SIGMAR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ALMIRALL, S.A. (ES) 2010-09-30 US disclosed
WO-2008116185-A2 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS NEUROCRINE BIOSCIENCES, INC. (US) 2008-09-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249084-A1 SUBSTITUTED PYRIMIDINES AS ADENOSINE RECEPTOR ANTAGONISTS ADORA3, ADORA1, ADORA2A ADORA2A 3/4885ADORA1 2/4885TSPO 3131/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.